Instil Bio, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 223.18 million compared to USD 156.79 million a year ago. Basic loss per share from continuing operations was USD 34.4 compared to USD 29.6 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.8 USD | +1.90% | +2.25% | +54.86% |
05-13 | Baird Adjusts Price Target on Instil Bio to $32 From $54, Maintains Outperform Rating | MT |
05-10 | Instil Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+54.86% | 76.75M | |
+26.37% | 48.16B | |
-1.01% | 41.73B | |
+46.00% | 41.03B | |
-5.31% | 28.77B | |
+9.34% | 25.59B | |
-21.69% | 18.96B | |
+6.23% | 12.92B | |
+26.99% | 12.03B | |
-3.38% | 11.77B |
- Stock Market
- Equities
- TIL Stock
- News Instil Bio, Inc.
- Instil Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022